Rosen Law Firm has filed securities class action lawsuits against Phreesia Inc., Zoetis Inc., and ChampionX Corporation on behalf of investors who purchased securities during specified periods. The lawsuits allege that defendants made false or misleading statements regarding business conditions, including slowing demand and reduced visibility in key revenue streams.

Robbins LLP is reminding investors of the July 27, 2026 lead plaintiff deadline in a class action lawsuit against Zoetis Inc. The lawsuit alleges that Zoetis misled investors about declining sales of flagship products including Librela, Simparica Trio, Apoquel, and Cytopoint due to FDA safety warnings, market competition, and market share losses. The company's stock fell 21.5% following disappointing Q1 2026 results and reduced full-year guidance.

A class action lawsuit has been filed against Zoetis Inc. alleging the company made false statements about its flagship companion animal products. The lawsuit claims Zoetis failed to disclose weakening demand for Librela, market share losses in Simparica Trio and dermatology products to competitors, and increased competitive pressures. Stock prices fell significantly following quarterly earnings announcements in August 2025 (4%), November 2025 (14%), and May 2026 (21%).

Bernstein Liebhard LLP has announced shareholder class action lawsuits against AeroVironment, Calix, and Zoetis. The lawsuits allege that the companies made materially false and misleading statements regarding their business operations, growth prospects, and financial stability, resulting in artificially inflated stock prices and significant investor losses.

Bernstein Liebhard LLP has announced shareholder class action lawsuits against three companies: Calix (CALX) for alleged misrepresentations regarding business operations and financial stability during January-April 2026; AeroVironment (AVAV) for shareholders between June 2025 and March 2026; and Zoetis (ZTS) for shareholders between January 2025 and May 2026. Investors are encouraged to contact the firm to discuss their rights and potential recovery.

Bernstein Liebhard LLP has announced shareholder class action lawsuits against three companies: Zoetis Inc. for alleged materially false and misleading statements regarding business operations and financial stability during January 2025-May 2026; Calix, Inc. for the period January-April 2026; and AeroVironment, Inc. for June 2025-March 2026. Investors who suffered losses are encouraged to contact the firm or file to become lead plaintiffs by specified deadlines.

A class action lawsuit has been filed against Zoetis Inc. alleging that the company made materially false and misleading statements regarding growth and market positioning of key products in its Companion Animal segment. The complaint claims Zoetis failed to disclose weakening veterinarian adoption of Librela due to FDA safety warnings, significant market share losses of Simparica Trio to competitors, and declining market share for dermatology products Apoquel and Cytopoint. The class period covers January 14, 2025 to May 6, 2026, with a lead plaintiff deadline of July 27, 2026.

Zoetis Inc. (NYSE: ZTS) shares fell approximately 21.5% on May 7, 2026, after the company slashed its full-year revenue guidance, citing weaker U.S. pet-care demand, macroeconomic pressure, and heightened competition. The guidance cut came less than three months after management had guided to 3-5% organic operational revenue growth. Levi & Korsinsky is investigating whether the company and its executives made materially misleading statements regarding revenue outlook and competitive positioning.

U.S. tech stocks reached record highs on May 7, 2026, as crude oil tumbled nearly 3% on hopes Iran will accept a U.S. memorandum to reopen the Strait of Hormuz. The Nasdaq 100 gained 0.4% to 28,706 while the S&P 500 rose 0.2% to 7,376. Earnings drove significant stock-specific moves, with major winners including AAON (+36%), Datadog (+30%), and H&R Block (+26%), while notable losers included Planet Fitness (-33%), Insmed (-22%), and Zoetis (-22%).

Despite current market volatility from geopolitical tensions, tariffs, and inflation concerns, historical indicators suggest investors should remain confident. The January barometer shows an 89% success rate for positive annual returns when January posts gains, shock events typically result in 7.4% median returns within 12 months, and markets have historically risen two out of every three years. Long-term investors are encouraged to continue adding to portfolios during market turbulence.

The article recommends Johnson & Johnson and Zoetis as excellent dividend stocks for income-oriented investors in 2026. Johnson & Johnson is praised for its consistent business, innovative pipeline including robotic surgery systems, and status as a Dividend King with 50+ consecutive annual dividend increases. Zoetis, an animal health company, is expected to overcome previous headwinds from safety concerns with newer osteoarthritis treatments and benefits from the trend of younger generations choosing pet ownership over having children.

The global veterinary reference laboratory market is projected to grow from USD 6.12 billion in 2025 to USD 13.93 billion by 2035, driven by rising pet ownership, pet humanization trends, and increased demand for advanced diagnostics. However, high infrastructure costs and shortage of skilled specialists pose challenges to market expansion.